Vanguard Investments Australia, Ltd.
Position in DNLI — Denali Therapeutics Inc.
CIK 1550100
Victoria, C3
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$962,185
+$243,913 QoQ
Shares Held
37,410
0.0% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#128
of 290 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vanguard Investments Australia, Ltd. holds $275,863,180 across 150 Biotechnology names. DNLI ranks #41 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130,109 | $64,629,043 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
52,947 | $33,014,572 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
67,644 | $20,362,873 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
77,334 | $14,483,111 | |
| 5 | RPRX |
Royalty Pharma plc
|
209,942 | $11,771,447 | |
| 6 | INSM |
INSMED Inc
|
106,644 | $11,370,383 | |
| 7 | INCY |
Incyte Corp
|
85,918 | $9,739,664 | |
| 8 | MRNA |
Moderna, Inc.
|
86,951 | $6,089,178 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $962,185 | 37,410 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $718,272 | 37,410 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||